Trial Profile
An Extension Study to Evaluate the Safety and Effectiveness of RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2018
Price :
$35
*
At a glance
- Drugs Carisbamate (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions
- Sponsors SK Life Science
- 02 Nov 2018 New trial record